MA
DRMA icon

MCF Advisors’s Dermata Therapeutics DRMA Stock Holding History

MCF Advisors’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.1K Buy
+1,732
New +$2.92K ﹤0.01% 1194

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

MCF Advisors's DRMA Position: Q1 2026 in Review

MCF Advisors opened a new position in Dermata Therapeutics (DRMA) in Q1 2026: 1,732 shares worth $2.1K. The stake represents ﹤0.01% of the portfolio and ranks #1194 among its holdings.

7 funds tracked by Wall St. Rank hold DRMA as of Q1 2026.

  • MCF Advisors held 1,732 shares of Dermata Therapeutics worth $2.1K as of Q1 2026.
  • Dermata Therapeutics was a new MCF Advisors position in Q1 2026.
  • Dermata Therapeutics made up ﹤0.01% of MCF Advisors's portfolio in Q1 2026, its #1194 holding.
  • 7 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2026.

Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.